ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor’s comments on the most important events at the 2006 conference.

Following the lackluster 2004 launch of an oral suspension formulation of Santarus’ lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus’ future success is tied to the commercial potential for the recently launched Z

There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum’s satraplatin, which could offer key advantages due to i

ASCO features key presentations in the oncology area, and is generally the most important week of the year for oncology. Presents Datamonitor’s comments on the most important events at the 2006 conference.

Surveyed physicians expect to continue to increase their use of Lidoderm in post-herpetic neuralgia and a variety of off-label pain conditions with use varying by specialty.

Palatin Technologies’ bremelanotide (PT-141) is a novel melanocortin receptor agonist that is believed to be the only agent currently in development for the treatment of both erectile dysfunction (ED) and female sexual dysfunction (FSD).

Renovis and AstraZeneca’s NXY-059 is viewed as the most promising neuroprotectant currently in development for stroke, however, much of its potential is dependent upon its ability to demonstrate a benefit in the recently enrolled SAINT-II trial.<

In May 2006 Bausch & Lomb’s ReNu with MoistureLoc contact lens solution was permanently withdrawn from markets worldwide due to an outbreak of a fungal eye infection. For a large market player, the loss of a new revenue driver and the negative pu

Digital imaging products and CEREC form the basis for growth for Sirona Dental Systems, while accounting for nearly two-thirds of revenues, and will therefore be essential to the newly formed combination of Schick Technologies and Sirona.

The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficu